Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Obagi Medical Unveils New Mineral Sunscreen Designed to Protect Sensitive and Post-Procedure Skin*

April 30, 2026

Wolverine and Metallica Scholars Turn Up the Volume on Skilled Trades with 2026 “Full Speed or Nothing” Collaboration

April 30, 2026

Lucasys Expands Beyond Utilities, Gaining Traction with Multiple Oil & Gas Customers

April 30, 2026

Antibody Contract Manufacturing Market Market Analysis Report 2026: $34.72 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 30, 2026

Polymarket and Bitget Wallet Launch Prediction Markets Report, Seeing Rising Retail Activity Reaching $25.7B Monthly Volume

April 30, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Endava
Press Release

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Endava

By News RoomSeptember 6, 20243 Mins Read
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Endava
Share
Facebook Twitter LinkedIn Pinterest Email

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Endava To Contact Him Directly To Discuss Their Options

If you suffered losses exceeding $100,000in Endava between May 23, 2023, and February 28, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

NEW YORK, Sept. 06, 2024 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Endava plc (“Endava” or the “Company”) (NYSE: DAVA) and reminds investors of the October 25, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose that: (1) demand for the Company’s services was declining; (2) the Company’s clients delayed or canceled projects; (3) as a result, the Company’s fiscal 2023 and 2024 revenue and earnings would be adversely affected; and (4), as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

As the truth about Endava’s business reached the market, the price of Endava’s stock suffered significant declines, harming investors. For example, on February 29, 2024, before the market opened, Endava filed a Form 6-K with the United States Securities and Exchange Commission, reporting revenues below expectations and drastically cutting revenue guidance for full year 2024. Endava attributed the revenue decline and reduced guidance to “clients [] hesitating on when to commit the sizable spend needed to build production-ready systems.”

On this news, the price of Endava’s common stock declined $26.65, or 42%, to close at $37.17, on unusually heavy trading.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Endava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Endava class action, go to www.faruqilaw.com/DAVA or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8ad14e1a-427f-432f-a0ed-55db0efbd018

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Obagi Medical Unveils New Mineral Sunscreen Designed to Protect Sensitive and Post-Procedure Skin*

Wolverine and Metallica Scholars Turn Up the Volume on Skilled Trades with 2026 “Full Speed or Nothing” Collaboration

Lucasys Expands Beyond Utilities, Gaining Traction with Multiple Oil & Gas Customers

Antibody Contract Manufacturing Market Market Analysis Report 2026: $34.72 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Polymarket and Bitget Wallet Launch Prediction Markets Report, Seeing Rising Retail Activity Reaching $25.7B Monthly Volume

Generic Pharmaceuticals Contract Manufacturing Market Analysis Report 2026: $93.56 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Bitget lists SKYAI (SKYAI) for Spot Trading

COVID-19 Detection Test Kits and Consumables Market Analysis Report 2026: $13.23 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Deoxycholic Acid Obesity Drugs Market Analysis Report 2026: $970 Mn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

Editors Picks

Wolverine and Metallica Scholars Turn Up the Volume on Skilled Trades with 2026 “Full Speed or Nothing” Collaboration

April 30, 2026

Lucasys Expands Beyond Utilities, Gaining Traction with Multiple Oil & Gas Customers

April 30, 2026

Antibody Contract Manufacturing Market Market Analysis Report 2026: $34.72 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 30, 2026

Polymarket and Bitget Wallet Launch Prediction Markets Report, Seeing Rising Retail Activity Reaching $25.7B Monthly Volume

April 30, 2026

Latest News

Generic Pharmaceuticals Contract Manufacturing Market Analysis Report 2026: $93.56 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 30, 2026

Bitget lists SKYAI (SKYAI) for Spot Trading

April 30, 2026

COVID-19 Detection Test Kits and Consumables Market Analysis Report 2026: $13.23 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F

April 30, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version